ArticleAnnals of medicine2025
Development and validation of a nomogram for predicting long-term survival in pN + esophageal squamous cell carcinoma treated using radical resection without neoadjuvant therapy.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of protein lysine lactylation and potential targets in esophageal squamous cell carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pN + status represents a crucial risk factor for esophageal squamous cell carcinoma (ESCC) patients without neoadjuvant therapy after radical resection. The necessity for adjuvant therapy post-surgery remains debatable. Our goal was to develop a personalized nomogram for predicting overall survival (OS) in pN + ESCC patients. MATERIALS AND
methodsThis study included 705 ESCC patients spanning from 1997 to 2016. All patients were staged according to the AJCC 8th edition TNM staging system and underwent radical resection without neoadjuvant therapy. The nomogram was constructed through univariate, multivariate, and LASSO Cox regression analyses. Its performance was evaluated and compared with the TNM staging system.
resultsThe training and external validation cohorts included 451 and 254 patients, respectively. Independent prognostic factors included age, history of drinking, thoracic duct ligation, pT stage, pN stage, length of ICU stay, and postoperative adjuvant chemotherapy. The AUC values of nomogram at 2- and 5-year intervals in the training cohort were 0.732 and 0.716, respectively, and 0.697 and 0.705 in the external validation cohort, respectively, both superior to the TNM staging system. The nomogram's effectiveness and stability were validated internally and externally, with significant OS differences observed among the various risk groups defined by the nomogram.
conclusionsThis study developed a prognostic nomogram for pN + ESCC patients who have not undergone neoadjuvant therapy and have undergone radical resection, providing superior predictive accuracy compared to the TNM staging system and easy to use in routine practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.